FX.co ★ Labcorp Gets De Novo Marketing Authorization For PGDx Elio Plasma Focus Dx Test

Labcorp (LH) has announced that it has received De Novo marketing authorization from the FDA for PGDx elio™ plasma focus Dx, the only kitted, pan-solid tumor liquid biopsy test available. This test is a significant addition to the company's precision oncology portfolio.

Shakti Ramkissoon, Vice President and Medical Lead for Oncology at Labcorp, stated, "This new liquid biopsy test offers laboratories and oncologists a convenient, cost-effective, and highly targeted tumor profiling solution applicable to a broad spectrum of solid tumor types, especially in scenarios where tumor tissue is limited or unavailable."